ctDNA and TCR Clonotype Detection for Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the efficacy of cancer immunotherapy are inadequate, as they rely on single biomarkers and radiographic imaging, which fail to accurately predict patient response or detect resistance, leading to suboptimal treatment outcomes.
Innovation Solution
Non-invasive methods involving the detection of circulating tumor DNA (ctDNA) and T-cell receptor (TCR) clonotype levels in biological samples at different time points, using techniques like targeted error-correction sequencing (TEC-Seq), to assess the effectiveness of immunotherapy and identify resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single biomarker-driven approaches are used to predict immunotherapy response, then the method is simple and easy to implement, but the accuracy of predicting patient response is insufficient
Solution Approach 1:
The patent combines multiple biomarkers (ctDNA levels, TCR clonotype levels, and other immune markers) into a composite assessment system. This merging of multiple detection targets allows for more accurate prediction of immunotherapy response while maintaining a unified detection platform that processes all markers simultaneously through next-generation sequencing.
Solution Approach 2:
The patent employs a composite biomarker profile consisting of multiple molecular indicators rather than relying on a single marker. This composite approach integrates information from tumor DNA fragmentation, T cell receptor diversity, and other immune-related molecules to create a comprehensive predictive model that overcomes the limitations of single-marker methods.
2Measurement precision
If current radiographic imaging methods are used to assess treatment response, then the methodology is established and widely available, but the response detection is delayed and less accurate
Solution Approach 1:
The patent performs molecular detection of treatment response before radiographic changes become visible. By monitoring ctDNA levels and TCR clonotype dynamics in blood samples early in the treatment course, the method predicts future radiographic response, allowing clinicians to assess treatment efficacy ahead of traditional imaging schedules and adjust therapy proactively.
Solution Approach 2:
The patent replaces mechanical radiographic imaging with molecular detection methods based on next-generation sequencing. This substitution detects biochemical changes in circulating tumor DNA and immune cell markers that precede anatomical changes visible on imaging, thereby eliminating the time delay inherent in radiographic assessment.
3Reliability
If single biomarker approaches are used, then the detection system is simple, but the system cannot accurately define which subset of patients will benefit from immunotherapy
Solution Approach 1:
The patent segments the patient population into distinct subsets based on their molecular biomarker profiles. By analyzing patterns across multiple markers including ctDNA fragmentation, TCR clonotype expansion, and other immune parameters, the system identifies specific patient subgroups with different probabilities of responding to immunotherapy, enabling personalized treatment selection.
Solution Approach 2:
The patent adds multiple dimensions to patient characterization by measuring various biomarkers simultaneously rather than relying on a single parameter. This multi-dimensional profiling approach creates a comprehensive molecular signature for each patient, allowing for more reliable stratification into treatment-responsive subsets through pattern recognition across multiple variables.
Data Source
AI summary
Provided herein are method of determining the efficacy of an immunotherapy in a subject by detecting changes in levels of circulating tumor DNA (ctDNA) and/or differences in TCR clonotype levels. Also provided herein are method of determining resistance to an immunotherapy in a subject by detecting changes in levels of circulating tumor DNA (ctDNA) and/or differences in TCR clonotype levels.